Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis-Reference-Cited by-同舟云学术

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis

Published:2017-05 Issue: Volume:77 Page:48-56
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Campiotti Leonardo^ORCID,Suter Matteo Basilio^ORCID,Guasti Luigina,Piazza Rocco^ORCID,Gambacorti-Passerini Carlo,Grandi Anna Maria,Squizzato Alessandro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference46 articles.

1. Chronic myelogenous leukemia;National Comprehensive Cancer Network,2015

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia;Baccarani;Blood,2013

3. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study;Talpaz;Blood,2002

4. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med,2010

5. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood,2012

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

2. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22

3. Treatment-Free Remission in Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-04-27

4. Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients;npj Systems Biology and Applications;2024-04-27

5. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study;Annals of Hematology;2024-04-03